Abstract
COVID-19 has led to morbidity in millions of patients, ranging from mild flu-like symptoms to severe respiratory failure, necessitating oxygen supplementation and mechanical ventilation, and ultimately death. The SARS-CoV-2 virus reacts with angiotensin-converting enzyme 2 (ACE2) molecules that are especially found in alveolar epithelial type 2 cells in the lungs and thereby causes a loss in lung surfactant, a protein-lipid mixture that is crucial for both native immunity and reduction of surface tension in the lung alveoli. Lung surfactant insufficiency results in atelectasis and loss of functional lung tissue amid an inflammatory storm and may be countered by treating COVID-19 pneumonia patients with exogenous lung surfactant, preferably by aerosol delivery of a novel dry powder synthetic lung surfactant. More research on timing, dosing, and delivery of synthetic lung surfactant in patients with COVID-19 pneumonia is of crucial importance to implement this approach in clinical practice.
Keywords: lung surfactant, alveolar type 2 cells, respiratory failure, SARS-CoV-2, COVID-19, pneumonia.
Coronaviruses
Title:Synthetic Lung Surfactant Treatment for COVID-19 Pneumonia
Volume: 2 Issue: 1
Author(s): Frans J. Walther*Alan J. Waring
Affiliation:
- Departments of Pediatrics and Internal Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA & The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California,United States
Keywords: lung surfactant, alveolar type 2 cells, respiratory failure, SARS-CoV-2, COVID-19, pneumonia.
Abstract: COVID-19 has led to morbidity in millions of patients, ranging from mild flu-like symptoms to severe respiratory failure, necessitating oxygen supplementation and mechanical ventilation, and ultimately death. The SARS-CoV-2 virus reacts with angiotensin-converting enzyme 2 (ACE2) molecules that are especially found in alveolar epithelial type 2 cells in the lungs and thereby causes a loss in lung surfactant, a protein-lipid mixture that is crucial for both native immunity and reduction of surface tension in the lung alveoli. Lung surfactant insufficiency results in atelectasis and loss of functional lung tissue amid an inflammatory storm and may be countered by treating COVID-19 pneumonia patients with exogenous lung surfactant, preferably by aerosol delivery of a novel dry powder synthetic lung surfactant. More research on timing, dosing, and delivery of synthetic lung surfactant in patients with COVID-19 pneumonia is of crucial importance to implement this approach in clinical practice.
Export Options
About this article
Cite this article as:
Walther J. Frans *, Waring J. Alan , Synthetic Lung Surfactant Treatment for COVID-19 Pneumonia, Coronaviruses 2021; 2 (1) : e160223186890 . https://dx.doi.org/10.2174/2666796701999201014160428
DOI https://dx.doi.org/10.2174/2666796701999201014160428 |
Print ISSN 2666-7967 |
Publisher Name Bentham Science Publisher |
Online ISSN 2666-7975 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance
Current Clinical Pharmacology Immunomodulatory and Anti-Inflammatory Activities of Statins
Endocrine, Metabolic & Immune Disorders - Drug Targets Texture-Based Classification of Periventricular Leukomalacia in Preterm Ultrasound Images
Current Medical Imaging A Review of Current Treatment Strategies for Varicose Veins
Recent Patents on Cardiovascular Drug Discovery Targeting RGD Recognizing Integrins: Drug Development, Biomaterial Research, Tumor Imaging and Targeting
Current Pharmaceutical Design Indication-oriented Ovulation Induction in Assisted Reproduction
Current Women`s Health Reviews Acute Fulminant Hepatatis in Kidney Transplant Recipient After Repeated Sevoflurane Anesthesia - A Case Report and Literature Review
Current Drug Safety Auto-Antibodies As Possible Markers and Mediators of Ischemic, Dilated, and Rhythmic Cardiopathies
Current Drug Targets Wound Repair - Updates in Dressing Patents and Regeneration Biomarkers
Recent Patents on Biomarkers Development and Evaluation of High Bioavailable Sustained-Release Nimodipine Tablets Prepared with Monolithic Osmotic Pump Technology
Current Drug Delivery Cardiac SPECT-CT and PET-CT Imaging
Current Medical Imaging Clinical Pharmacokinetics of Systemically Administered Antimycotics
Current Clinical Pharmacology Importance and Limitations of Chemotherapy Among the Available Treatments for Gastrointestinal Tumours
Anti-Cancer Agents in Medicinal Chemistry Postpartum Haemorrhage, A Persisting Killer Around the Globe, Road Ahead
Current Women`s Health Reviews Shear Stress-sensitive Carriers for Localized Drug Delivery
Current Pharmaceutical Design Bivalirudin or Heparin Treatment During Transcatheter Valve Interventions: Where are we Now?
Current Pharmaceutical Design Hemolysis-Associated Pulmonary Hypertension in Sickle Cell Disease: Global Disruption of the Arginine-Nitric Oxide Pathway
Current Hypertension Reviews Microparticles: From Biogenesis to Biomarkers and Diagnostic Tools in Cardiovascular Disease
Current Stem Cell Research & Therapy A Hyperlipidemic Diet Induces Structural Changes in Cerebral Blood Vessels
Current Neurovascular Research Diagnosis and Treatment of Unilateral Forms of Primary Aldosteronism
Current Hypertension Reviews